Skip to main content

Optimal cultivation of Chlamydia requires testing of serum on individual species



This report is a side product of experiments aimed at identifying serum for culturing obligate intracellular bacteria Chlamydia trachomatis and C. muridarum in mouse fibroblast L929 cells.


Of five commercial serum samples tested, two showed optimal efficiencies at supporting growth of the human pathogen Chlamydia trachomatis as control fetal bovine serum, whereas two showed modest ~ 40% inhibitions in progeny production, and the remaining one showed a 20% inhibition. Three of the six sera poorly supported growth of the murine pathogen Chlamydia muridarum, resulting in 73–90% reduction in progeny formation. Most significantly, the one with the strongest (90%) C. muridarum inhibition activity showed optimal C. trachomatis-supporting efficiency. These findings indicate that in laboratories that study multiple Chlamydia species, serum samples should be prescreened on a species basis. Considering Chlamydial biology and epidemiology, it may even be necessary to perform serum tests on a serovar- or strain-basis for studying some animal chlamydiae.


Animal serum serves as a rich source of growth factors for culturing animal cells [1] and intracellular pathogens requiring animal cells as hosts (e.g., [2,3,4,5]). Fetal bovine serum (FBS), which contains a large and diverse group of growth factors, has been a popular choice. However, the high costs of FBS (due to its limited supplies) and ethical concerns associated with its production have led some researchers to pursue using other alternatives to FBS, including newborn calf serum (NBCS, defined as serum collected from calves that are less than 10 days old) and horse serum [1,2,3,4,5].

Chlamydia is a genus of bacteria that replicates only inside host eukaryotic cells [6]. Chlamydia trachomatis and C. pneumoniae are common human pathogens. Whereas C. trachomatis is the number one sexually transmitted pathogenic bacterium [7], C. pneumoniae causes communicable respiratory infections [8]. Other Chlamydia species known as pathogens of animals including livestock may cause severe illness in humans after their contact with infected animals [9]. C. psittaci, cause of psittacosis, is the best example of zoonotic Chlamydia. C. muridarum is a mouse pathogen. Although C. muridarum infection in humans has never been documented, it is the most widely studied animal Chlamydia, owing to its capacity to model human chlamydial infections in mouse [10, 11].

Like many laboratories, our laboratory studies both C. trachomatis and C. muridarum. In an event evaluating commercial serum samples, we found differential effects of the sera on the two Chlamydia species. These findings mandate prescreening sera for individual species in laboratories that study multiple species.

Main text


Animal serum

Samples of FBS, NBCS and ASC were supplied by American Type Culture Collection (ATCC), Atlantic Biologicals, Gemini Bio-products and Sigma Millipore. Prior to use, all serum samples as well as control FBS (Sigma Millipore) were subjected to heat inactivation (56 °C, 30 min) to eliminate adverse effects of complements on chlamydiae [12].

Evaluation of effects of serum on chlamydial growth

Mouse fibroblast L929 cells were used as host for chlamydiae. They were grown as adherent cultures using the Dulbecco modified Eagle’s medium containing 4.5 g/L glucose and 0.11 g/L sodium pyruvate (DMEM) and supplemented with 5% (vol/vol) control FBS and gentamicin (final concentration: 10 µg/ml). To evaluate the effects of serum samples on chlamydial growth, cells were seeded onto 6-well plates and cultured overnight to 90% confluency. Elementary body (EB) stocks of C. trachomatis L2 (strain 434/Bu) (CtL2) and C. muridarum (strain Nigg) (Cm) [13] were diluted in DMEM containing 5% serum samples and 1 µg/ml cycloheximide, which promotes chlamydial growth by inhibiting host cellular protein synthesis. To infect the cells, the overnight culture media were replaced with the EB-containing medium (2 ml/well). The multiplicity of infection was 0.5 inclusion-forming unit (IFU) per cell. After culture at 37 °C for 30 h (Cm) or 36 h (CtL2), the culture media were replaced with 100 μL of sucrose–phosphate–glutamate buffer, and cells were detached from the plastic surface using a Cell Lifter, and collected into a 5 ml culture tube. Tubes were then placed on ice and subject to brief sonication to release chlamydiae from cells [13]. The sonicated harvests were serially diluted in a 1:10 manner and then inoculated onto L929 monolayers grown on 96 well plates, which were fixed with cold methanol following 30 h (Cm) or 36 h (CtL2) incubation at 37 °C. Cm and CtL2 inclusions were reacted with a mouse polyclonal anti-Cm antibody [14] and a monoclonal anti-major outer membrane protein antibody (clone L2-1-5) [15], respectively, followed by fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG (Sigma-Aldrich). Inclusions were scored under an Olympic IX51 fluorescence microscope.


We tested a total of 5 serum samples from commercial sources along with a control fetal bovine serum (CFBS) on the growth of C. trachomatis L2 (CtL2) and C. muridarum (Cm). Among the five serum samples, three were fetal bovine sera (i.e., FBS1-3), one was a newborn calf serum (i.e., NBCS1), and the last one was known as animal serum complex (i.e., ASC1), of which the compositions were not disclosed by the manufacturer. CFBS had been tested previously and used for culturing both Ct and Cm for more than a year in our lab prior to this work. Compared with CFBS, FBS1 or NBCS1 demonstrated similar and the most desirable effect on CtL2 growth, resulting in the highest EB yields (Fig. 1a). FBS2 showed a slight 21% decrease in EB production, which was deemed statistically insignificant (P = 0.009). FBS3 and ASC1 demonstrated suboptimal effects on chlamydial growth, resulting in statistically significant 41% and 40% decreases, respectively, in EB production (Fig. 1a).

Fig. 1

Differential seral effects on CtL2 (a) and Cm (b) growth. Averages ± standard deviations of recoverable inclusion-forming units of progeny EBs from quadruplicate tests are presented. Asterisks signify statistically significant EB yield decreases as compared to the control CFBS (P < 0.005)

Compared to CtL2, Cm displayed mostly contrasting responses to the serum products (Fig. 1b). Among all samples tested, only FBS2 showed a similar effect on Cm growth as CFBS. FBS1, which was optimal for CtL2 growth, was suboptimal for Cm, resulting in only 68% progeny EBs, compared to CFBS. Most interestingly, NBCS1, which was optimal for CtL2 growth, had the most detrimental effect on Cm growth, resulting in a 90% EB production inhibition. FBS3, which had a suboptimal effect on CtL2 growth, displayed a similarly severe adverse effect as NBCS1, leading to an 88% reduction in EB production. ASC1, which had a suboptimal effect on CtL2 growth (40% inhibition in EB yield), exhibited a more severe adverse effect on Cm growth, giving rise to a 73% decrease.


The importance of serum in culturing chlamydiae was recognized starting more than four decades ago (e.g., [2, 3]). However, previous studies reporting effects of different serum products on chlamydial growth were performed with only single species [2,3,4,5]. In this work, we have demonstrated that some animal sera have significantly different effects on Ct and Cm growth. Although we have not determined the underlying mechanism, we suspect anti-chlamydia antibodies are responsible for the observed inhibitory effects. Ct and Cm are known to infect only human and mouse, respectively. However, multiple other Chlamydia species, namely C. pecorum and C. abortus, C. pneumoniae, C. psittaci and C. gallinacean are known to infect cows [9, 16]. Thus, it should not be surprising if FBS or NBCS contains anti-chlamydia antibodies because maternal IgG is capable of entering the fetal blood stream. Although genomes of Chlamydia species are highly conserved, they express different polymorphic proteins on the cell surface. These proteins serve as immunodominant antigens, which induce hosts to produce neutralizing antibodies [17, 18]. Other outer membrane proteins including the major outer membrane protein are also immunodominant proteins [19]. Thus, the effects of a particular serum on Ct and Cm would be determined by antibodies with cross reactivity for the organisms (or not).

Surface-exposed domains of the major outer membrane protein are immunodominant epitopes [20, 21]. They are highly variable even within the same Chlamydia species [20, 21]. While our findings mandate serum testing for individual Chlamydia species for optimal cultivation, tests may be necessary for individual serovars of Chlamydia species capable of infecting cows. Perhaps, serum testing should be performed for individual strains of Chlamydia species without well-established serovars.


We make the recommendation of serum testing on individual Chlamydia species on the basis of data presented in Fig. 1. However, the suggestion of serum testing for different serovars or strains within some animal chlamydial species is made without experimental evidence.

Availability of data and materials

The dataset used for this study is available from the corresponding author on request.



animal serum complex


control fetal bovine serum


Chlamydia muridarum


Chlamydia trachomatis serovar L2


Dulbecco’s Modified Eagle Medium


fetal bovine serum


inclusion forming unit


newborn calf serum


  1. 1.

    Yao T, Asayama Y. Animal-cell culture media: history, characteristics, and current issues. Reprod Med Biol. 2017;16(2):99–117.

    Article  Google Scholar 

  2. 2.

    Allan I, Pearce JH. Serum modulation of cell susceptibility to chlamydial infection. FEMS Microbiol Lett. 1977;1(4):211–3.

    Article  Google Scholar 

  3. 3.

    Karayiannis P. HOBSON D: the role of calf serum in the growth of Chlamydia trachomatis in McCoy cell cultures. Microbiology. 1981;122(1):47–54.

    CAS  Article  Google Scholar 

  4. 4.

    LaScolea LJ Jr, Baldigo SM. Infectivity of Chlamydia trachomatis in tissue culture with newborn calf serum. J Clin Microbiol. 1982;15(5):951–3.

    Article  Google Scholar 

  5. 5.

    Levy NJ, Benes S, McCormack WM. Growth of host cells and Chlamydia trachomatis in medium containing serum from 16-week-old calves. J Clin Microbiol. 1983;17(1):68–71.

    CAS  Article  Google Scholar 

  6. 6.

    Borel N, Greub G. International Committee on Systematics of Prokaryotes (ICSP) Subcommittee on the taxonomy of Chlamydiae. Minutes of the closed meeting, 5 July 2018, Woudschoten, Zeist, The Netherlands. Int J Syst Evol Microbiol. 2019;69(8):2606–8.

    Article  Google Scholar 

  7. 7.

    WHO: Global prevalence and incidence of selected curable sexually transmitted infections: Overview and estimates. 2001.

  8. 8.

    Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288(21):2724–31.

    CAS  Article  Google Scholar 

  9. 9.

    Cheong HC, Lee CYQ, Cheok YY, Tan GMY, Looi CY, Wong WF. Chlamydiaceae: diseases in primary hosts and zoonosis. Microorganisms. 2019;7(5):146.

    Article  Google Scholar 

  10. 10.

    Zhong G. Chlamydia spreading from the genital tract to the gastrointestinal tract—a two-hit hypothesis. Trends Microbiol. 2018;26(7):611–23.

    CAS  Article  Google Scholar 

  11. 11.

    de la Maza L, Pal S, Khamesipour A, Peterson E. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun. 1994;62(5):2094–7.

    Article  Google Scholar 

  12. 12.

    Yang Z, Conrad T, Zhou Z, Chen J, Dutow P, Klos A, Zhong G. Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum. Infect Immun. 2014;82(8):3154–63.

    Article  Google Scholar 

  13. 13.

    Bao X, Gylfe A, Sturdevant GL, Gong Z, Xu S, Caldwell HD, Elofsson M, Fan H. Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner. J Bacteriol. 2014;196(16):2989–3001.

    Article  Google Scholar 

  14. 14.

    Zhang H, Kunadia A, Lin Y, Fondell JD, Seidel D, Fan H. Identification of a strong and specific antichlamydial N-acylhydrazone. PLoS ONE. 2017;12(10):e0185783.

    Article  Google Scholar 

  15. 15.

    Zhang YX, Stewart SJ, Caldwell HD. Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect Immun. 1989;57(2):636–8.

    CAS  Article  Google Scholar 

  16. 16.

    Li J, Guo W, Kaltenboeck B, Sachse K, Yang Y, Lu G, Zhang J, Luan L, You J, Huang K, et al. Chlamydia pecorum is the endemic intestinal species in cattle while C. gallinacea, C. psittaci and C. pneumoniae associate with sporadic systemic infection. Vet Microbiol. 2016;193:93–9.

    Article  Google Scholar 

  17. 17.

    Crane DD, Carlson JH, Fischer ER, Bavoil P, Hsia RC, Tan C, Kuo CC, Caldwell HD. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A. 2006;103(6):1894–9.

    CAS  Article  Google Scholar 

  18. 18.

    Tan C, Hsia RC, Shou H, Haggerty CL, Ness RB, Gaydos CA, Dean D, Scurlock AM, Wilson DP, Bavoil PM. Chlamydia trachomatis—infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. Infect Immun. 2009;77(8):3218–26.

    CAS  Article  Google Scholar 

  19. 19.

    Caldwell HD, Perry LJ. Neutralization of Chlamydia trachomatis infectivity with antibodies to the major outer membrane protein. Infect Immun. 1982;38(2):745–54.

    CAS  Article  Google Scholar 

  20. 20.

    Zhang YX, Stewart S, Joseph T, Taylor HR, Caldwell HD. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. J Immunol. 1987;138(2):575–81.

    CAS  PubMed  Google Scholar 

  21. 21.

    Zhong G, Berry J, Brunham RC. Antibody recognition of a neutralization epitope on the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1994;62(5):1576–83.

    CAS  Article  Google Scholar 

Download references


We thank Dr. Harlan D. Caldwell (National Institute of Allergy and Infectious Diseases) for supplying the L2-1-5 antibody.


This work was supported by the National Institutes of Health (Grant # AI140167), and New Jersey Health Foundation (Grant # PC 20–18). The funders played no role in the study design, execution and publication.

Author information




All authors (MD, HZ and HF) participated in the experimental design. MD and HZ performed the experiments. MD wrote the first draft of the manuscript, which was reviewed and edited first by HZ and HF, and then by MD. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Huizhou Fan.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Desai, M., Zhang, H. & Fan, H. Optimal cultivation of Chlamydia requires testing of serum on individual species. BMC Res Notes 13, 28 (2020).

Download citation


  • Chlamydia trachomatis
  • Chlamydia muridarum
  • Fetal bovine serum
  • Serum test